Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
118 hedge funds and large institutions have $1.82B invested in Principia Biopharma Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 41 increasing their positions, 45 reducing their positions, and 17 closing their positions.
391% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $495K
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
14% more capital invested
Capital invested by funds: $1.6B → $1.82B (+$218M)
3% more funds holding
Funds holding: 115 → 118 (+3)
9% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$40.2M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$25.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$28.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$27M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$26.9M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$10.1M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$7.76M |
PRNB Hedge Fund Activity: Q1 2020 in Review
118 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q1 2020, worth a combined $1.82B — up 14% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRNB positions and 17 closed out — a net gain of 4 holders — while 41 added to existing stakes and 45 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $40.3M. The largest seller was New Leaf Venture Partners, cutting an estimated $28.7M.
- 118 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q1 2020, up from 115 in Q4 2019.
- Funds reported $1.82B of Principia Biopharma Inc. Common Stock stock for Q1 2020, up 14% quarter-over-quarter.
- 21 funds opened new Principia Biopharma Inc. Common Stock positions in Q1 2020 and 17 closed out, a net change of +4 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q1 2020 was Citadel Advisors, an estimated $40.3M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q1 2020 was New Leaf Venture Partners, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2020.